Finding a Blockbuster Successor to Lipitor
Back in 2008, Pfizer (www.pfizer.com) strategically delayed generic competition for its blockbuster statin product Lipitor (atorvastatin) by some 20 months until November 2011. By settling global patent disputes with Ranbaxy Laboratories (www.ranbaxy.com), a generic drug maker in India that had thre...
Gespeichert in:
| Veröffentlicht in: | Genetic engineering & biotechnology news 2011-02, Vol.31 (3), p.16-17 |
|---|---|
| 1. Verfasser: | |
| Format: | Magazinearticle |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 17 |
|---|---|
| container_issue | 3 |
| container_start_page | 16 |
| container_title | Genetic engineering & biotechnology news |
| container_volume | 31 |
| creator | Dimond, P F |
| description | Back in 2008, Pfizer (www.pfizer.com) strategically delayed generic competition for its blockbuster statin product Lipitor (atorvastatin) by some 20 months until November 2011. By settling global patent disputes with Ranbaxy Laboratories (www.ranbaxy.com), a generic drug maker in India that had threatened to market its own version of Lipitor, Pfizer hung on to the majority of the cholesterol-lowering market. |
| doi_str_mv | 10.1089/gen.31.03.05 |
| format | Magazinearticle |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_860383059</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>860383059</sourcerecordid><originalsourceid>FETCH-LOGICAL-p187t-cae993072cb5e1813ed65127de89c80f62ab0e288a02c2de279cd8c389d9cfd43</originalsourceid><addsrcrecordid>eNotzLFOwzAQAFAPIFEKGx-QDQkp4Ww38d0IFQWkSAwtElvlnC9VIMQhTv6fAaa3PaVuNBQakO5PMhRWF2ALKM_USpMt840zHxfqMqVPgMqQo5W623VD6IZT5rPHPvJXs6RZpmy_MEtKccrmmNXd2M1xulLnre-TXP-7Vu-7p8P2Ja_fnl-3D3U-anRzzl6ILDjDTSkatZVQldq4IEiM0FbGNyAG0YNhE8Q44oBskQJxGzZ2rW7_3nGKP4uk-fjdJZa-94PEJR2xAosWSrK_sDxDGA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>magazinearticle</recordtype><pqid>860383059</pqid></control><display><type>magazinearticle</type><title>Finding a Blockbuster Successor to Lipitor</title><source>Alma/SFX Local Collection</source><creator>Dimond, P F</creator><creatorcontrib>Dimond, P F</creatorcontrib><description>Back in 2008, Pfizer (www.pfizer.com) strategically delayed generic competition for its blockbuster statin product Lipitor (atorvastatin) by some 20 months until November 2011. By settling global patent disputes with Ranbaxy Laboratories (www.ranbaxy.com), a generic drug maker in India that had threatened to market its own version of Lipitor, Pfizer hung on to the majority of the cholesterol-lowering market.</description><identifier>ISSN: 1935-472X</identifier><identifier>DOI: 10.1089/gen.31.03.05</identifier><language>eng</language><ispartof>Genetic engineering & biotechnology news, 2011-02, Vol.31 (3), p.16-17</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784,27925</link.rule.ids></links><search><creatorcontrib>Dimond, P F</creatorcontrib><title>Finding a Blockbuster Successor to Lipitor</title><title>Genetic engineering & biotechnology news</title><description>Back in 2008, Pfizer (www.pfizer.com) strategically delayed generic competition for its blockbuster statin product Lipitor (atorvastatin) by some 20 months until November 2011. By settling global patent disputes with Ranbaxy Laboratories (www.ranbaxy.com), a generic drug maker in India that had threatened to market its own version of Lipitor, Pfizer hung on to the majority of the cholesterol-lowering market.</description><issn>1935-472X</issn><fulltext>true</fulltext><rsrctype>magazinearticle</rsrctype><creationdate>2011</creationdate><recordtype>magazinearticle</recordtype><recordid>eNotzLFOwzAQAFAPIFEKGx-QDQkp4Ww38d0IFQWkSAwtElvlnC9VIMQhTv6fAaa3PaVuNBQakO5PMhRWF2ALKM_USpMt840zHxfqMqVPgMqQo5W623VD6IZT5rPHPvJXs6RZpmy_MEtKccrmmNXd2M1xulLnre-TXP-7Vu-7p8P2Ja_fnl-3D3U-anRzzl6ILDjDTSkatZVQldq4IEiM0FbGNyAG0YNhE8Q44oBskQJxGzZ2rW7_3nGKP4uk-fjdJZa-94PEJR2xAosWSrK_sDxDGA</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Dimond, P F</creator><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20110201</creationdate><title>Finding a Blockbuster Successor to Lipitor</title><author>Dimond, P F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p187t-cae993072cb5e1813ed65127de89c80f62ab0e288a02c2de279cd8c389d9cfd43</frbrgroupid><rsrctype>magazinearticle</rsrctype><prefilter>magazinearticle</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Dimond, P F</creatorcontrib><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Genetic engineering & biotechnology news</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dimond, P F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Finding a Blockbuster Successor to Lipitor</atitle><jtitle>Genetic engineering & biotechnology news</jtitle><date>2011-02-01</date><risdate>2011</risdate><volume>31</volume><issue>3</issue><spage>16</spage><epage>17</epage><pages>16-17</pages><issn>1935-472X</issn><abstract>Back in 2008, Pfizer (www.pfizer.com) strategically delayed generic competition for its blockbuster statin product Lipitor (atorvastatin) by some 20 months until November 2011. By settling global patent disputes with Ranbaxy Laboratories (www.ranbaxy.com), a generic drug maker in India that had threatened to market its own version of Lipitor, Pfizer hung on to the majority of the cholesterol-lowering market.</abstract><doi>10.1089/gen.31.03.05</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1935-472X |
| ispartof | Genetic engineering & biotechnology news, 2011-02, Vol.31 (3), p.16-17 |
| issn | 1935-472X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_860383059 |
| source | Alma/SFX Local Collection |
| title | Finding a Blockbuster Successor to Lipitor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A57%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Finding%20a%20Blockbuster%20Successor%20to%20Lipitor&rft.jtitle=Genetic%20engineering%20&%20biotechnology%20news&rft.au=Dimond,%20P%20F&rft.date=2011-02-01&rft.volume=31&rft.issue=3&rft.spage=16&rft.epage=17&rft.pages=16-17&rft.issn=1935-472X&rft_id=info:doi/10.1089/gen.31.03.05&rft_dat=%3Cproquest%3E860383059%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=860383059&rft_id=info:pmid/&rfr_iscdi=true |